Gyre Therapeutics stock gains 1.57 percent after upgrade

Published on 10/04/2026 at 14:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gyre Therapeutics stock drew a Sell to Hold rating change on October 3, 2026. Q2 revenue reached USD 29.11 million, while GAAP basic EPS missed consensus.

GYRE, US4037831033, Illustration mit AI erstellt.

Gyre Therapeutics stock (ISIN US4037831033) gained 1.57 percent to USD 7.11 on Nasdaq on October 2, 2026, after Wall Street Zen upgraded the rating from Sell to Hold on October 3, 2026. The move puts a recent analyst change against a second-quarter loss and a revenue outlook that still calls for contraction in fiscal 2026.

Rating change meets a cautious consensus

According to MarketBeat on October 3, 2026, Wall Street Zen moved Gyre from Sell to Hold. The same report said one analyst rated the stock Buy and two rated it Sell, producing a Reduce consensus and an average price target of USD 16.00.

That target lies 125.0 percent above the October 2 reference price of USD 7.11. The spread reflects the market's central tension: the pipeline offers substantial development potential, while recent earnings remain loss-making.

Q2 revenue beat did not prevent a loss

Gyre reported second-quarter 2026 revenue of USD 29.11 million and GAAP basic EPS of negative USD 0.12, according to EODHD. MarketBeat reported that revenue exceeded the USD 26.49 million consensus estimate, while the loss was wider than the expected negative USD 0.06 per share.

The company also affirmed fiscal 2026 revenue guidance of USD 100.5 million to USD 111.0 million in the same Q2 update, a range that places the quarterly result in the context of a year focused on regulatory progress and commercial execution.

Stock remains below its yearly high

At USD 7.11, Gyre traded between its USD 5.44 52-week low and USD 9.42 52-week high on October 2, 2026. Market capitalization was USD 792.7 million and reported volume was 163,746 shares for that session.

For investors, the next test is whether clinical and regulatory progress can narrow the gap between the USD 7.11 market price and the USD 16.00 consensus target while the company manages quarterly losses.